Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis

Thorax

Volumn 63, Issue 8, 2008, Pages 749-

  Horton, M R ^a   Danoff, S K ^a   Lechtzin, N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIZZINESS; DRUG WITHDRAWAL; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; LETTER; OPEN STUDY; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; WILCOXON SIGNED RANKS TEST;

EID: 49149123869     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2008.098699     Document Type: Letter

References (5)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-64.
2. Hope-Gill BD, Hilldrup S, Davies C, et al. A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:995-1002.
3. Forrester JC, Ury HK. The signed-rank (Wilcoxon) test in the rapid analysis of biological data. Lancet 1969;1:239-41.
4. Madison JM, Irwin RS. Chronic cough in adults with interstitial lung disease. Curr Opin Pulm Med 2005;11:412-16.
5. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082- 5.